Content Library
Exclusive, Tailor-Made Content for You!
The Microbiome space is rapidly accelerating, and as Europe’s premiere microbiome conference tightly focused on the development of microbiome-based therapeutics, we aim to capture wide perspectives from key leaders and organizations for your benefit.
Speaker Interview - Rafik Fellague-Chebra, Executive Group Medical Director, Novartis Oncology
Interested in hearing Novartis’ thoughts on cancer biology and interactions with microbes? Your exclusive access to our interview with Rafik Fellague-Chebra, one of our 45+ expert speakers is just a few clicks away!
Don't miss his insights, and remember - we have very limited slots remaining for the summit. Register today for the chance to meet and network with key leaders in the industry!
Your Christmas Present is Just A Few Clicks Away - Full 2023 Microbiome Report from Beacon
Access the entire report for free, complete with compelling infographics and industry news from 2023 that you can use to get ahead of the curve in 2024!
A Chat with Magali Cordaillat-Simmons, Executive Director, Pharmabiotic Research Institute
"We know that from the cell therapy field, some potency tests didn't take into account the microenvironment and this might have an impact on the results of phase three for these cell therapies. For the microbiome field, it is important to start considering these aspects as well. It comes back to the analytical methods question, how do we better understand the microenvironment in which we will do our intervention based on patient specificities and the environment?" says Magali Cordaillat-Simmons, Executive Director at the Pharmabiotic Research Institute (PRI).
We had the pleasure of speaking with Magali who identifies the key regulatory science challenges, shares her thoughts on 'pharmaco-microbiomics' as well as how platforms like the 8th Microbiome Movement- Drug Development Summit Europe can help address such challenges.